Mymetics Corp. (MYMX) news stock charts
Mymetics Corp. (MYMX/MYMX.OB) Investment Summary:
Mymetics Corporation, a biotechnology research and development company, engages in fundamental and applied research in the area of human biology and medicine. The company primarily focuses on the development of vaccines and therapies to prevent and treat the effects of various retroviruses that primarily include human immunodeficiency virus (HIV). It also engages in the research of potential treatments and vaccines for malaria, human oncoviral leukemias, multiple sclerosis, and organ transplantation. The company, formerly known as ICHOR Corporation, was founded in 1990 and is based in Nyon, Switzerland.www.mymetics.com
7 Employees
Founded in 1990
MYMETICS CORP (MYMX:OTC Bulletin Board Market)
LAST $0.17 USD
CHANGE TODAY 0.00 0.00%
VOLUME 75.0K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of MYMETICS CORP (MYMX)
|
OPEN
$0.18
|
PREVIOUS CLOSE
$0.17
|
|
|
DAY HIGH
$0.18
|
DAY LOW
$0.17
|
|
|
52 WEEK HIGH
03/20/09 - $0.20
|
52 WEEK LOW
12/21/09 - $0.09
|
|
|
MARKET CAP
33.3M
|
AVERAGE VOLUME 10 D
59.1K
|
|
|
EPS TTM
$-0.06
|
SHARES OUTSTANDING
196.1M
|
|
|
MYMX Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for MYMETICS CORP (MYMX)
Mymetics Corporation Announces Management Changes
09/9/2009
Mymetics Corporation announced the progression of Mymetics' Scientific Advisory Board with the appointment of Dr. Stanley Plotkin as the Chairman of the revised Scientific Advisory Board. The role of the Scientific Advisory Board, under the chairmanship of Dr. Plotkin, will be to provide expert scientific advice as well as to provide assistance in raising funds from foundations, governments and other nonprofit organizations. Chairman of the Scientific Advisory Board-Dr. Stanley Plotkin, Emeritus Professor Wistar Institute, consultant to Sanofi Pasteur, developed the rubella vaccine in 1960s; worked extensively on the development and application of other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus as well as senior roles at the Epidemic Intelligence Service, U.S. Public Health Service; Aventis Pasteur (medical and scientific director); and Sanofi Pasteur (executive advisor). Vice Chairman of the Scientific Advisory Board-Dr. Marc Girard, has over 20 years of experience in the development of an HIV vaccine, is a past Director of the Merieux Foundation and a consultant to the WHO and former Chairman of EuroVac (European Consortium for HIV vaccine). Dr. Morgane Bomsel, Cochin Institute, France, Dr. Ruth Ruprecht, Harvard University, Dana Farber Cancer Institute, Boston, USA, Dr. Ronald H. Gray, Johns Hopkins University, Baltimore, USA, Dr. Malegapuru William Makgoba, University of KwaZulu-Natal, Durban, South Africa, Dr. Souleymane Mboup, Cheikh Anta DIOP University, Dakar, Senegal, Dr. Juliana McElrath, University of Washington, Seattle, USA, Dr. Odile Puijalon, Institut Pasteur, Paris, France and Dr. Caetano Reis e Sousa, Cancer Research UK, London, UK.
Mymetics Corporation announced delayed 10-Q filing
08/14/2009
On 08/14/2009, Mymetics Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Mymetics Corp. Appoints Jacques Francois Martin as Director, Chairman, President and CEO Effective July 1, 2009
06/25/2009
Mymetics Corp. through its Board of Directors, elected Jacques Francois Martin to be a member of the Board to fill a vacancy on the Board. In addition, the Board elected Mr. Martin to be Chairman of the Board. Mr. Martin is currently Chairman and CEO of Parteurop SAS. Mr. Martin also agreed to become the President and CEO of Mymetics effective July 1, 2009.
Mymetics Corp. financial resources
MYMX Competitors
| Company | Last | Change | |
| No competitor information is available for MYMX. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | MYMX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 128.5x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
MYMX |
||
|
MYMX transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Mymetics Corp.
Mymetics Corporation: The First Human Vaccinations of Mymetics' Preventative HIV Vaccine Candidate are Well Tolerated
2010-03-05 03:28:44
Quote: 19, 2010 (GLOBE NEWSWIRE) -- Mymetics Corporation, a pioneer in the development of mucosal focused vaccines for human infectious diseases, announced today that following the vaccination of human volunteers as part of a clinical Phase I trial, the company's first preventative HIV vaccine has been well tolerated. This Phase I trial follows the breakthrough results Mymetics has achieved in macaque monkeys last year. During these pre-clinical studies Mymetics' HIV vaccine provided full protection of...Read article
Mymetics Corporation: The First Human Vaccinations of Mymetics' Preventative HIV Vaccine Candidate are Well Tolerated
2010-02-25 06:56:14
Quote: 19, 2010 (GLOBE NEWSWIRE) -- Mymetics Corporation, a pioneer in the development of mucosal focused vaccines for human infectious diseases, announced today that following the vaccination of human volunteers as part of a clinical Phase I trial, the company's first preventative HIV vaccine has been well tolerated.This Phase I trial follows the breakthrough results Mymetics has achieved in macaque monkeys last year. During these pre-clinical studies Mymetics' HIV vaccine provided full protection of ...Read article
Mymetics Corporation: The First Human Vaccinations of Mymetics' Preventative HIV Vaccine Candidate are Well Tolerated
2010-01-20 02:31:17
Quote: 19, 2010 (GLOBE NEWSWIRE) -- Mymetics Corporation, a pioneer in the development of mucosal focused vaccines for human infectious diseases, announced today that following the vaccination of human volunteers as part of a clinical Phase I trial, the company’s first preventative HIV vaccine has been well tolerated.This Phase I trial follows the breakthrough results Mymetics has achieved in macaque monkeys last year. During these pre-clinical studies Mymetics' HIV vaccine provided full protect...Read article
Mymetics Corporation Announces the Appointment of Dr. Stanley Plotkin as Chairman of the Scientific Advisory Board and Election of New Members
2010-01-12 02:59:21
Quote: www.mymetics.comMYMXNews), announced today the progression of Mymetics' Scientific Advisory Board with the appointment of Dr. Stanley Plotkin as the Chairman of the revised Scientific Advisory Board.
"The role of the Scientific Advisory Board, under the chairmanship of Dr. Plotkin, will be to provide expert scientific advice as well as to provide assistance in raising funds from foundations, governments and other nonprofit organizations," stated Jacques-Francois Martin. "We look forward to the ...Read article
Mymetics Corporation's Board of Directors Announces the Appointment of Jacques-Francois Martin as President and CEO
2010-01-12 02:59:21
Quote: www.mymetics.comMYMXNews), today announced that its Board of Directors has named Jacques-Francois Martin as Chairman of the Board, President and CEO, effective July 1, 2009, replacing Christian Rochet who remains as a non executive Director.
"I am impressed with the quality of the science developed by Mymetics and look forward to leveraging the company's diverse technologies," stated Jacques-Francois Martin. "We will continue to develop our science and build on the existing pre-clinical and cli...Read article
Mymetics Corporation Presents Ground Breaking Results With Preventative HIV Vaccine at the World AIDS Vaccine Congress in Paris 19 - 22 October
2010-01-12 02:59:20
Quote: Results show high mucosal protection against repeated live SHIV vaginal challenges after vaccination with Mymetics' preventative HIV-1 vaccine candidate. The vaccinated group showed no detectable viremia while the placebo group became fully infected.
"We are very pleased to share our results with the scientific community attending to the world leading congress on AIDS vaccines," commented Dr. Sylvain Fleury, Chief Scientific Officer of Mymetics Corp; "The results are very encouraging and we bel...Read article
MYMETICS CORP Files SEC form 10-Q, Quarterly Report
2009-11-30 07:57:05
Quote: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
The following discussion and analysis of the results of operations and financial
condition of Mymetics Corporation for the periods ended March 31, 2009 and 2008
should be read in conjunction with the Company's audited consolidated financial
statements for the year ended December 31, 2008 and related notes and the
description of the Company's business and properties included elsewhere herein.
This...Read article
Mymetics Corporation Completes Important Acquisition
2009-11-30 07:57:05
Quote: http://www.mymetics.comMYMX.OBNewsNIM.LNews) as per the terms
of the LOI described in the form 8-k filed on March 5, 2009.http://www.globenewswire.com/newsroom/prs/?pkgid=5478Safe Harbor Forward-Looking Statements? Statements contained
in this release that are not strictly historical are ``forward-looking
statements''. Such forward-looking statements are sometimes
identified by words such as ``intends'', ``anticipates'', ``believes'',
``expects'' and ``hopes''. The forward-looking statements are...Read article
Mymetics Corporation Announces the Appointment of Dr. Stanley Plotkin as Chairman of the Scientific Advisory Board and Election of New Members
2009-11-30 07:57:04
Quote: www.mymetics.comMYMXNews), announced today the progression of Mymetics' Scientific Advisory Board with the appointment of Dr. Stanley Plotkin as the Chairman of the revised Scientific Advisory Board.
"The role of the Scientific Advisory Board, under the chairmanship of Dr. Plotkin, will be to provide expert scientific advice as well as to provide assistance in raising funds from foundations, governments and other nonprofit organizations," stated Jacques-Francois Martin. "We look forward to the ...Read article
MYMETICS CORP Files SEC form 10-Q, Quarterly Report
2009-11-30 07:57:04
Quote: ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
The following discussion and analysis of the results of operations and financial
condition of Mymetics Corporation for the periods ended June 30, 2009 and 2008
should be read in conjunction with the Company's audited consolidated financial
statements for the year ended December 31, 2008 and related notes and the
description of the Company's business and properties included elsewhere herein....Read article
MYMETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers
2009-11-30 07:57:04
Quote: Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The registrant ("Mymetics"), through its Board of Directors, elected Jacques
Francois Martin to be a member of the Board to fill a vacancy on the Board. In
addition, the Board elected Mr. Martin to be Chairman of the Board. Mr. Martin
became a member of the Mymetics Board effective June 23, 2009. Mr. Martin is the
former CEO of ...Read article
MYMETICS CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Sec
2009-11-30 07:57:04
Quote: Completion of Acquisition or Disposition of Assets.
On March 5, 2009, the registrant ("Mymetics") and Norwood Immunology Limited
("NIL") entered into a Share Purchase Agreement pursuant to which Mymetics
agreed to purchase all issued and outstanding shares of capital stock (the
"Bestewil Shares") of Bestewil Holding B.V. ("Bestewil") from its parent,
Norwood Immunology Limited ("NIL"), and all issued and outstanding shares of
capital stock of V...Read article
MYMETICS CORP Files SEC form 10-Q, Quarterly Report
2009-11-30 07:57:03
Quote: ITEM 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
The following discussion and analysis of the results of operations and financial
condition of Mymetics Corporation for the periods ended September 30, 2009 and
2008 should be read in conjunction with the Company's audited consolidated
financial statements for the year ended December 31, 2008 and related notes and
the description of the Company's business and properties included elsewhere
he...Read article
Mymetics Corporation Presents Ground Breaking Results With Preventative HIV Vaccine at the World AIDS Vaccine Congress in Paris 19 - 22 October
2009-11-30 07:57:03
Quote: Results show high mucosal protection against repeated live SHIV vaginal challenges after vaccination with Mymetics' preventative HIV-1 vaccine candidate. The vaccinated group showed no detectable viremia while the placebo group became fully infected.
"We are very pleased to share our results with the scientific community attending to the world leading congress on AIDS vaccines," commented Dr. Sylvain Fleury, Chief Scientific Officer of Mymetics Corp; "The results are very encouraging and we bel...Read article
Mymetics Corporation's Board of Directors Announces the Appointment of Jacques-Francois Martin as President and CEO
2009-11-27 22:05:05
Quote: NYON, Switzerland, June 26, 2009 (GLOBE NEWSWIRE) -- Mymetics (www.mymetics.com) Corporation (OTCBB:MYMX - News), today announced that its Board of Directors has named Jacques-Francois Martin as Chairman of the Board, President and CEO, effective July 1, 2009, replacing Christian Rochet who remains as a non executive Director.
"I am impressed with the quality of the science developed by Mymetics and look forward to leveraging the company's diverse technologies," stated Jacques-Francois Martin. ...Read article
Would you like to leave a comment about Mymetics Corp. MYMX/MYMX.OB
Find out what social network information about Mymetics Corp. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Mymetics Corp.'s Stock there is more great penny stock and market information at Realpennies